Conba subsidiary gains approval for key respiratory drug

Zhejiang Conba Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jinhua Conba Biological Pharmaceutical Co., Ltd., has received a drug registration certificate for Ipratropium Bromide and Salbutamol Sulfate Inhalation Solution from the National Medical Products Administration. The inhaled preparation, specified as 2.5ml: ipratropium bromide 0.5mg and salbutamol sulfate 2.5mg, is classified as a chemical drug Category 4.

The drug, originally developed by Boehringer Ingelheim, treats reversible bronchospasm associated with obstructive airway diseases and has been marketed in China since 2006. Jinhua Conba submitted its application in January 2024 and invested approximately RMB 7.9 million in its research and development. This approval, considered equivalent to passing generic drug consistency evaluation, is expected to positively impact the company’s performance.

With this approval, Jinhua Conba joins 21 other domestic manufacturers of this drug, which is included in China's 2024 National Medical Insurance Drug Catalogue. In 2024, the domestic retail and medical terminal markets for Ipratropium Bromide and Salbutamol Sulfate Inhalation Solution recorded total sales of RMB 240 million.